388 related articles for article (PubMed ID: 10773226)
1. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.
Spinale FG; Coker ML; Bond BR; Zellner JL
Cardiovasc Res; 2000 May; 46(2):225-38. PubMed ID: 10773226
[TBL] [Abstract][Full Text] [Related]
2. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure.
Spinale FG; Coker ML; Heung LJ; Bond BR; Gunasinghe HR; Etoh T; Goldberg AT; Zellner JL; Crumbley AJ
Circulation; 2000 Oct; 102(16):1944-9. PubMed ID: 11034943
[TBL] [Abstract][Full Text] [Related]
3. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy.
Thomas CV; Coker ML; Zellner JL; Handy JR; Crumbley AJ; Spinale FG
Circulation; 1998 May; 97(17):1708-15. PubMed ID: 9591765
[TBL] [Abstract][Full Text] [Related]
4. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure.
Coker ML; Thomas CV; Clair MJ; Hendrick JW; Krombach RS; Galis ZS; Spinale FG
Am J Physiol; 1998 May; 274(5):H1516-23. PubMed ID: 9612358
[TBL] [Abstract][Full Text] [Related]
5. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function.
Spinale FG; Coker ML; Thomas CV; Walker JD; Mukherjee R; Hebbar L
Circ Res; 1998 Mar; 82(4):482-95. PubMed ID: 9506709
[TBL] [Abstract][Full Text] [Related]
6. Extracellular degradative pathways in myocardial remodeling and progression to heart failure.
Spinale FG; Gunasinghe H; Sprunger PD; Baskin JM; Bradham WC
J Card Fail; 2002 Dec; 8(6 Suppl):S332-8. PubMed ID: 12555141
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases: regulation and dysregulation in the failing heart.
Spinale FG
Circ Res; 2002 Mar; 90(5):520-30. PubMed ID: 11909815
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices.
Li YY; Feng Y; McTiernan CF; Pei W; Moravec CS; Wang P; Rosenblum W; Kormos RL; Feldman AM
Circulation; 2001 Sep; 104(10):1147-52. PubMed ID: 11535571
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
[TBL] [Abstract][Full Text] [Related]
10. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system.
Pauschinger M; Chandrasekharan K; Schultheiss HP
Heart Fail Rev; 2004 Jan; 9(1):21-31. PubMed ID: 14739765
[TBL] [Abstract][Full Text] [Related]
11. [Mechanisms of extracellular matrix remodeling in dilated cardiomyopathy].
Pauschinger M; Chandrasekharan K; Li J; Schwimmbeck PL; Noutsias M; Schultheiss HP
Herz; 2002 Nov; 27(7):677-82. PubMed ID: 12439639
[TBL] [Abstract][Full Text] [Related]
12. Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling.
Wei Y; Cui C; Lainscak M; Zhang X; Li J; Huang J; Zhang H; Zheng Z; Hu S
J Cell Mol Med; 2011 Apr; 15(4):773-82. PubMed ID: 20219015
[TBL] [Abstract][Full Text] [Related]
13. Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium.
Wilson EM; Spinale FG
Ann Med; 2001 Dec; 33(9):623-34. PubMed ID: 11817657
[TBL] [Abstract][Full Text] [Related]
14. Determinants of extracellular matrix remodelling are differentially expressed in paediatric and adult dilated cardiomyopathy.
Hsia TY; Ringewald JM; Stroud RE; Forbus GA; Bradley SM; Chung WK; Spinale FG
Eur J Heart Fail; 2011 Mar; 13(3):271-7. PubMed ID: 21147820
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy.
Schwartzkopff B; Fassbach M; Pelzer B; Brehm M; Strauer BE
Eur J Heart Fail; 2002 Aug; 4(4):439-4. PubMed ID: 12167381
[TBL] [Abstract][Full Text] [Related]
16. Novel approaches to retard ventricular remodeling in heart failure.
Spinale FG
Eur J Heart Fail; 1999 Mar; 1(1):17-23. PubMed ID: 10937974
[TBL] [Abstract][Full Text] [Related]
17. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.
Li YY; McTiernan CF; Feldman AM
Cardiovasc Res; 2000 May; 46(2):214-24. PubMed ID: 10773225
[TBL] [Abstract][Full Text] [Related]
18. Myocardial extracellular matrix remodeling in ischemic heart failure.
Gallagher GL; Jackson CJ; Hunyor SN
Front Biosci; 2007 Jan; 12():1410-9. PubMed ID: 17127391
[TBL] [Abstract][Full Text] [Related]
19. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation.
Nishikawa N; Yamamoto K; Sakata Y; Mano T; Yoshida J; Miwa T; Takeda H; Hori M; Masuyama T
Cardiovasc Res; 2003 Mar; 57(3):766-74. PubMed ID: 12618238
[TBL] [Abstract][Full Text] [Related]
20. Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig.
Goetzenich A; Hatam N; Zernecke A; Weber C; Czarnotta T; Autschbach R; Christiansen S
J Heart Lung Transplant; 2009 Oct; 28(10):1087-93. PubMed ID: 19782292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
